APOA1 Rabbit pAb for WB, IHC-P, IF/ICC, ELISA - P02647

Core Product Specifications and Parameters

Biological Background: APOA1 Function and Localization

• Apolipoprotein A-I (APOA1) is the major protein component of plasma high-density lipoprotein (HDL) and is also found in chylomicrons.
• It plays a central role in reverse cholesterol transport by promoting cholesterol efflux from tissues and acting as a cofactor for lecithin cholesterol acyltransferase (LCAT), facilitating cholesterol esterification and clearance.
• As part of the seminal plasma sperm-activating protein (SPAP) complex, APOA1 contributes to the activation of spermatozoa motility.
• APOA1 is a secreted protein synthesized primarily in the liver and small intestine, circulating in plasma as a component of HDL particles.
• The protein undergoes oxidative modifications at Met-110 and Met-136; these oxidized forms are elevated in individuals at higher risk for coronary artery disease, including carriers of the eNOSa/b genotype and smokers, and are enriched in aortic lesions with increasing disease severity.
• APOA1 belongs to a family of apolipoproteins involved in lipid transport and metabolism, with annotations linking it to cholesterol metabolism, steroid metabolism, and atherosclerosis.
• Post-translational modifications include glycation, phosphorylation, palmitoylation, and nitration, which may modulate its function and pathological roles in amyloidosis and neuropathy.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the mature protein sequence (amino acids 25-267), covering a large portion of APOA1; this region is conserved across human, mouse, and rat, supporting the reported cross-reactivity.
• For Western blotting, APOA1 is predicted to migrate at approximately 28 kDa, but post-translational modifications and HDL particle association may cause shifts; validate band size in your sample system using appropriate positive controls (e.g., human plasma, liver lysates).
• In immunohistochemistry (IHC-P), APOA1 is primarily localized in the extracellular space and cytoplasm of hepatocytes and enterocytes; optimize antigen retrieval and consider co-staining with HDL markers to confirm specificity.
• For immunofluorescence (IF/ICC), note that APOA1 is secreted; intracellular staining may reflect newly synthesized protein in the endoplasmic reticulum/Golgi; use serum-free conditions or pulse-chase to enhance detection.
• The antibody has been validated for ELISA; due to its polyclonal nature, it may recognize multiple epitopes, potentially offering enhanced sensitivity in sandwich ELISA setups when paired with a suitable capture antibody.
• Always include controls from relevant species (human, mouse, rat) and tissues (liver, small intestine, plasma) to confirm experimental specificity.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio supports diagnostic manufacturers and research laboratories with a comprehensive portfolio of IVD raw materials, including validated polyclonal and monoclonal antibodies for cardiovascular and metabolic disease targets like APOA1. Beyond this anti-APOA1 antibody, we provide matched antibody pairs, optimized bulk ancillary reagents, and custom sourcing for rare targets to accelerate your assay development from concept to clinic. Let CamelBio be your reliable partner in securing high-quality raw materials for your next diagnostic innovation.